A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
NCT00701415
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
31
Enrollment
INDUSTRY
Sponsor class
Conditions
Fabry Disease
Interventions
BIOLOGICAL:
Agalsidase beta
BIOLOGICAL:
Agalsidase beta
Sponsor
Genzyme, a Sanofi Company